Login to Your Account

Antibiotic Returned to Anacor; GSK Discontinues Development

By Catherine Shaffer
Staff Writer

Friday, October 5, 2012

Eight months after suspending Phase I/II trials of Anacor Pharmaceuticals Inc.'s systemic antibiotic, GSK2251052, GlaxoSmithKline plc has dropped the other shoe by discontinuing development of the compound.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription